Neuroimmunology Explained: When the Immune System Targets the Brain

• Introduction
• Chapter 1 Fundamentals of Neuroimmunology: Cells, Signals, and Circuits
• Chapter 2 The Blood–Brain Barrier and the Neurovascular Unit in Health and Disease
• Chapter 3 Antigen Presentation and Breakdown of Immune Tolerance in the CNS
• Chapter 4 B Cells, Plasma Cells, and Pathogenic Antibodies in the Brain
• Chapter 5 Microglia, Complement, and Disordered Synapse Pruning
• Chapter 6 Cytokine Networks and the Orchestration of Neuroinflammation
• Chapter 7 Neuroimaging of Inflammation: MRI, PET, and Advanced Techniques
• Chapter 8 Cerebrospinal Fluid and Biomarkers: From Oligoclonal Bands to Neurofilament Light
• Chapter 9 Diagnostic Approach to Suspected Autoimmune Neurologic Disease: A Practical Algorithm
• Chapter 10 Multiple Sclerosis: Clinical Phenotypes and Natural History
• Chapter 11 Multiple Sclerosis: Diagnostic Criteria, Differentials, and Pitfalls
• Chapter 12 Disease‑Modifying Therapies for Multiple Sclerosis: Mechanisms, Selection, and Monitoring
• Chapter 13 Autoimmune Encephalitis: Syndromic Clues and Antibody‑Specific Phenotypes
• Chapter 14 Limbic Encephalitis and Psychiatric Presentations
• Chapter 15 Paraneoplastic Neurologic Syndromes: Onconeural Antibodies and Cancer Screening
• Chapter 16 Aquaporin‑4 Neuromyelitis Optica Spectrum Disorder: Pathogenesis and Care Pathways
• Chapter 17 MOG Antibody–Associated Disease and Related Demyelinating Syndromes
• Chapter 18 CNS Vasculitis, Neurosarcoidosis, and Systemic Autoimmunity Affecting the Brain
• Chapter 19 Pediatric and Adolescent Considerations in Neuroimmunology
• Chapter 20 Pregnancy, Postpartum, and Family Planning in Autoimmune Neurologic Disease
• Chapter 21 Acute Therapies: Corticosteroids, IVIG, and Plasma Exchange
• Chapter 22 Long‑Term Immunotherapies: Rituximab, Mycophenolate, Azathioprine, and Beyond
• Chapter 23 Targeted and Emerging Therapies: Complement Inhibitors, IL‑6 Blockade, BTK Inhibitors, and Cell‑Based Strategies
• Chapter 24 Infections, Vaccines, and Safety on Immunotherapy: Preventing and Managing Complications
• Chapter 25 Case Vignettes and Decision‑Making Algorithms Across Disorders

When the immune system turns its formidable arsenal toward the central nervous system, the results can be as devastating as they are bewildering. Neuroimmunology seeks to explain how adaptive and innate immune mechanisms intersect with neural circuits, glia, and the blood–brain barrier to shape health and disease. Over the past two decades, discoveries of pathogenic antibodies, refinements in imaging, and breakthroughs in targeted therapies have transformed once‑mysterious syndromes into diagnoses with concrete, timely treatments. Yet at the bedside, clinicians still confront uncertainty: distinguishing autoimmune encephalitis from infection or primary psychiatric illness; deciding when to treat urgently without complete serologic confirmation; or tailoring long‑term immunotherapy while balancing infectious risks, comorbidities, and patient preferences. This book aims to bridge cutting‑edge science with practical, clinician‑friendly guidance.

Our organizing principle is clinical problem‑solving. We begin with foundational immunology as it pertains to the brain: how tolerance fails, how microglia and complement sculpt synapses, and how cytokine networks propagate or restrain inflammation. We then translate these mechanisms into diagnostic logic—what patterns on MRI imply active demyelination versus vasculitis, which cerebrospinal fluid profiles steer suspicion toward autoimmunity, when autoantibody testing changes management, and how to avoid common pitfalls such as false positives or over‑reliance on single biomarkers. Throughout, emphasis is placed on pretest probability, time‑sensitive decisions, and stepwise algorithms that integrate history, examination, imaging, CSF, and serology.

The core disease sections focus on conditions every neurologist and immunologist must recognize early: multiple sclerosis, autoimmune encephalitis, and neuromyelitis optica spectrum disorder, along with MOG antibody–associated disease and key mimics such as CNS vasculitis and neurosarcoidosis. For each, you will find concise overviews of pathogenesis linked to actionable care pathways: what clinical features are “red flags,” which tests should be ordered immediately, how to interpret ambiguous results, and how to select therapies based on disease activity, prognostic markers, and individual life context. Chapters highlight differences across age groups, attention to cognitive and psychiatric manifestations, and strategies for longitudinal monitoring.

Therapeutics are presented from the bedside backward: start with the problem (acute deterioration or relapsing activity), choose among corticosteroids, IVIG, or plasma exchange for rapid control, and then build a sustainable long‑term plan. We review established immunotherapies and the rationale behind them, outline safety monitoring and infection prevention, and discuss the expanding toolkit of targeted options—including complement inhibition, IL‑6 pathway blockade, B‑cell depletion, and emerging small‑molecule and cellular strategies. Rather than cataloging drugs in isolation, we anchor choices in phenotypes, comorbidities, reproductive planning, and patient goals, emphasizing shared decision‑making and risk mitigation.

Because neuroimmunologic syndromes frequently blur specialty boundaries, this book integrates perspectives from psychiatry, oncology, rheumatology, and infectious diseases. Readers will find guidance on cancer screening in paraneoplastic syndromes, vaccine timing around immunotherapy, and management during pregnancy and the postpartum period. We also address health‑system realities: access to specialized testing, interpretation of send‑out antibody panels, infusion logistics, and the practical steps that ensure equitable, timely care.

Every major section ends with algorithms and case vignettes distilled from real‑world scenarios—patients who improved because a clinician recognized a pattern, or who reminded us where biases and shortcuts can mislead. These narratives serve as teachable moments, illustrating how to apply concepts under uncertainty and how to course‑correct when initial hypotheses prove wrong. They also underscore an encouraging truth: in many autoimmune neurologic conditions, early recognition and decisive therapy can prevent disability and restore function.

Finally, neuroimmunology is a moving target. New autoantibodies are discovered, diagnostic criteria evolve, and therapeutic landscapes shift with each trial. Our goal is not to freeze the field but to provide durable frameworks—mechanistic understanding, diagnostic discipline, and principled treatment strategies—that will remain useful as specifics change. If, by the end, you feel more confident navigating from symptom onset to definitive care while partnering effectively with patients and colleagues, this book will have achieved its purpose.

The human brain, an organ of unparalleled complexity, was long considered an "immune-privileged" sanctuary, largely shielded from the body's vigilant immune system. This notion stemmed from the observation that the central nervous system (CNS) lacked conventional lymphatic drainage and exhibited restricted entry for immune cells, a protective measure seemingly designed to prevent inflammatory damage to delicate neural tissue. However, this classical view has undergone a profound re-evaluation. We now understand that the brain and the immune system are in constant, intricate dialogue, a dynamic interplay essential for both CNS health and disease. Neuroimmunology, at its heart, is the study of this fascinating conversation.

The Brain's Resident Immune Sentinels: Glial Cells

Within the CNS, a specialized cast of non-neuronal cells, collectively known as glia, play pivotal roles in maintaining brain homeostasis and orchestrating immune responses. These include microglia, astrocytes, and oligodendrocytes, each with unique functions and a surprising capacity to act as immune cells.

Microglia, often dubbed the brain's resident macrophages, are the primary active immune defenders of the CNS. They originate from myeloid precursor cells and colonize the CNS early in development. In their resting state, they constantly survey the brain parenchyma with their highly branched processes, acting as vigilant sensors for any signs of injury, infection, or aberrant changes. When activated by various stimuli, they rapidly transform, migrating to sites of damage or infection, where they phagocytose cellular debris, damaged neurons, toxic protein aggregates, and infectious agents. Microglia also contribute to synaptic pruning during brain development and adulthood, a crucial process for refining neural circuits. They secrete a variety of signaling molecules, including cytokines and chemokines, to influence other immune cells and facilitate tissue repair. However, chronic or dysregulated microglial activation can contribute to neuroinflammation and neuronal damage.

Astrocytes are the most abundant glial cells in the CNS and are critical for brain homeostasis. They perform a wide array of functions, from supporting neuron metabolism and modulating neurotransmitter release to regulating cerebral blood flow and maintaining the integrity of the blood-brain barrier. Beyond these supportive roles, astrocytes are also immunocompetent cells, capable of initiating and tuning cerebral immune responses. They can sense molecules produced by peripheral immune cells, including cytokines, and contribute to both protective and inflammatory responses. Astrocytes can secrete a broad range of pro-inflammatory mediators, proteases, and cytotoxins, but also anti-inflammatory cytokines and growth factors, playing a crucial role in the resolution of inflammation. The concept of astrocytes existing in a bimodal "resting" or "activated" state is evolving, with evidence suggesting a more nuanced, multimodal activation, including pro-inflammatory (A1) and neuroprotective (A2) phenotypes.

Oligodendrocytes, best known for forming the myelin sheath that insulates axons and ensures efficient nerve impulse conduction, also possess immune-inflammatory functions. Oligodendrocyte precursor cells (OPCs), also known as NG2-glia, persist in the adult brain and play a role in maintaining microglia in a surveillant state. Upon CNS injury, oligodendrocytes express various inflammatory mediators and receptors for immune-related molecules, allowing them to sense and react to inflammation. They can produce cytokines and chemokines, regulating immune cell migration and activation within the CNS. Furthermore, oligodendrocytes can express Major Histocompatibility Complex (MHC) class I and II molecules, enabling them to present antigens to T cells and influence immune tolerance.

The Peripheral Immune System's Envoys: T and B Lymphocytes

While traditionally thought to be excluded from the CNS, T and B lymphocytes, key players in adaptive immunity, do traffic into the brain, particularly during neuroinflammatory conditions. Their presence and activity are crucial in autoimmune neurological disorders.

T cells, or T lymphocytes, are central to cell-mediated immunity. They recognize specific antigens presented by MHC molecules on antigen-presenting cells. In the context of neuroimmunology, activated T cells can infiltrate the CNS and contribute to inflammation and tissue damage. Their differentiation into various subtypes, such as Th1, Th2, and Th17, determines the nature of the immune response. Immune checkpoints, such as PD-1 and CTLA-4, are critical regulators of T cell function, preventing excessive immune activation. These checkpoints are expressed by various CNS-resident cells, including microglia, astrocytes, oligodendrocytes, neurons, and endothelial cells, and are often upregulated during inflammation.

B cells, or B lymphocytes, are responsible for humoral immunity, primarily through the production of antibodies. While their activation and maturation largely occur in peripheral lymphoid tissues, antigen-experienced B cells can migrate into and out of the CNS. In autoimmune CNS diseases, B cells activated in the periphery can produce pathogenic autoantibodies that diffuse into the CNS, contributing to neuroinflammation and neuronal damage. There is also evidence suggesting that B cells can undergo further maturation and expansion within the intrathecal compartment, potentially forming ectopic germinal center-like structures.

Signaling Molecules: The Language of Neuroimmunity

The intricate dialogue between immune cells and neural tissue is mediated by a complex repertoire of signaling molecules, including cytokines, chemokines, and neurotransmitters.

Cytokines are a diverse group of soluble proteins that act as messengers between cells, regulating immune responses, inflammation, and cellular growth and differentiation. They are produced by both immune and non-immune cells, including glial cells and neurons within the CNS. Cytokines can have pro-inflammatory effects, such as IL-1β, IL-6, and TNF-α, or anti-inflammatory properties, helping to balance immune activation. They play a critical role in CNS homeostasis, neuronal development, and synaptogenesis, but their overexpression can contribute to neurotoxic and neurodegenerative disorders. Cytokines can cross the blood-brain barrier, influencing brain function and behavior, and interact with neuroendocrine systems.

Chemokines are a specialized subset of cytokines primarily known for their ability to induce cell migration. They act through G-protein-coupled receptors and are involved in diverse functions beyond chemotaxis, including brain development, homeostasis, and cell proliferation and differentiation. In the CNS, chemokines are constitutively expressed by microglia, astrocytes, and neurons, and their expression can increase during inflammation. They play an essential role in neuroinflammation by mediating leukocyte infiltration, and their overexpression has been implicated in various neurological disorders like multiple sclerosis. Certain homeostatic chemokines, such as CXCL12 and CX3CL1, are crucial for maintaining CNS homeostatic functions, regulating neurogenesis, neuronal survival, and communication between neurons and microglia.

Neurotransmitters, traditionally seen as chemical messengers solely within the nervous system, are now recognized as key modulators of the immune system. Immune cells produce neurotransmitters and express their receptors, allowing for bidirectional communication between the nervous and immune systems. Neurotransmitters like serotonin, dopamine, norepinephrine, glutamate, and GABA can influence various aspects of immune function, including inflammation and the activity of different immune cell types. Imbalances in neurotransmitter-mediated immune regulation can contribute to various health issues, including autoimmune diseases.

The Complement System: An Innate Immune Powerhouse with a Nuanced Role

The complement system, a crucial component of innate immunity, is a cascade of plasma proteins that traditionally aids antibodies in clearing pathogens and damaged cells. However, its role extends far beyond simple pathogen defense, with significant implications for CNS development, function, and disease.

Within the brain, the complement system is involved in both normal neuronal development and inflammatory processes. Neurons, astrocytes, and microglia can all produce complement components and receptors. While complement is generally understood to be produced in the liver and circulate in the bloodstream, local production within the brain is critical, with limited involvement from circulating complement.

One of the most intriguing discoveries regarding complement in the CNS is its role in synaptic pruning, a physiological process essential for optimizing neural circuitry. Complement components like C1q and C3, often in conjunction with microglia, selectively tag and remove weak or unused synapses during postnatal brain development. This process, while vital for healthy brain development, can become dysregulated in neurodegenerative and inflammatory conditions, leading to excessive synapse loss.

The complement system's activation can be triggered by various danger signals, both exogenous (pathogen-associated molecular patterns) and endogenous (damage-associated molecular patterns), through classical, lectin, or alternative pathways. While complement activation is critical for protection against microbial threats and clearing cellular debris, its rapid and uncontrolled activation after brain injury can lead to significant tissue damage. The delicate balance of complement activation is crucial, as both protective and detrimental effects have been observed, depending on the context, timing, and intensity of the stimuli.